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Background: Fluorescent imaging agents are becoming evermore important in preclinical and clinical research.
They do, however, suffer from poor tissue penetration, which makes optical fluorescence imaging incompatible
with whole-body imaging techniques. The design of novel bimodal PET active and fluorescent tracers could
therefore combine the benefits of optical imaging with radioactively labeled imaging probes. Herein, we report the
synthesis and evaluation of a clickable 18F-labeled fluorescent dye.
Methods: An azide-modified BODIPY-Fl dye could be successfully radio-labeled with 18F using an 18F/19F exchange
reaction of the boron-fluoride core of the BODIPY dye to yield a clickable bimodal PET/fluorescent imaging tool. In
vitro as well as in vivo imaging (PET/fluorescence) using a bombesin analog was conducted to study the
applicability of the dual-modality imaging probe.
Results: We use the radio-labeled small molecule, 18F-BODIPY-azide to label site-specifically different targeted
peptides, based on a standard modular labeling protocol. Following the synthesis of a bimodal bombesin analog,
we determine the peptide tracer’s performance in vitro and in vivo, exploring both the optical as well as PET
imaging capabilities.
Conclusion: This versatile methodology has the potential to have a transformational impact on 18F radiotracer
synthesis, opening the door for rapid screening of novel-labeled peptide tracers, both on the cellular (optical) as
well as whole-body (PET) level.Background
Positron emission tomography (PET) allows non-invasive
whole-body imaging by detecting pairs of gamma rays, a
secondary product of positron decay of radionuclides.
Among the commonly used radionuclides for PET, 18F is
often the radioelement of choice due to its relatively short
half-life and multifaceted chemistry. However, the spatial
resolution of PET is limited and cannot detect microscopic
lesions or resolve the heterogeneity of tissues at the cellular
level [1]. In contrast, optical fluorescence imaging has very
high spatial resolution, making it a valuable technique for
the development of intraoperative imaging agents [2–4].
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Therefore, dual-modality imaging probes have the po-
tential to combine the advantages of both imaging tech-
niques and allow imaging from the whole-body down to
the cellular level [5]. Two major challenges in the devel-
opment of dual-modality imaging agents are the usually
increased synthetic complexity and the effect of the
fluorescent dye on the biodistribution of the imaging
agent. In order to reduce the steric impact resulting
from the conjugation of a bimodal imaging tag to a
small peptide ligand, we got interested in 18F/19F ex-
change reactions used to transform fluorescent dyes into
dual-modality PET/fluorescent imaging dyes [6–10]. The
advantage of this approach is that a targeting molecule
is only modified at a single site, allowing both optical
and PET labeling without increased steric demand, low-
ering the chances of compromising targeting efficiency.
In comparison to previous reports, we wanted to go ais distributed under the terms of the Creative Commons Attribution 4.0
ns.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
give appropriate credit to the original author(s) and the source, provide a
ndicate if changes were made.
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the previously described 18F/19F exchange reaction with
the BODIPY-Fl dye—which can be site-specifically con-
jugated to biomarkers in the second step.
Herein, we describe a synthetic method for labeling
peptides with a modular 18F/19F-labeling protocol, allow-
ing the fast and rapid design of multiple optical/PET la-
beled peptides with just one radio-labeled synthetic
intermediate. Specifically, our approach is based on a
18F/19F exchange reaction of a BODIPY-Fl dye which is
then coupled to peptides by a click reaction. We use
four different targeted peptides to show the general ap-
plicability of our approach, and test one bimodal bombe-
sin receptor targeting peptide in a PC-3 prostate cancer
model, both in vitro as well as in vivo.
Methods
Materials
Commercially available compounds were used without fur-
ther purification unless otherwise stated. Alkyne-modified
bombesin analog (RM2-alkyne, BBN) (Leu-Sta-His-Gly-
Val-Ala-Trp-Gln-D-Phe-4-amino-1-carboxymethyl-piperi-
dine-4-pentynoic acid) was synthesized with a peptide
synthesizer (Rainin/Protein Technologies) and purified by
high performance liquid chromatography (HPLC) using a
reversed phase XTerra® preparative column (C18, 10 μm,
19 mm × 250 mm). Alkyne-modified exendin-4 (E4x12),
CCK2, and pHLIP were purchased from C S Bio Co.
(Menlo Park, CA). [125I-Tyr4]-bombesin was purchased
from Perkin Elmer (Boston, MA). BODIPY-Fl N-hydro-
xysuccinimidyl (NHS) ester was purchased from Life
Technologies (Carlsbad, CA). Phosphate buffered sa-
line (PBS) and Dulbecco’s Modified Eagle Medium
(DMEM) were purchased from the media preparation
facility at Memorial Sloan Kettering Cancer Center
(New York, NY, USA). PC-3, a human prostate cancer
cell line was purchased from ATCC (Manassas, VA).
All HPLC purifications (1.0 mL/min, buffer A; 0.1 %
TFA in water, buffer B; 0.1 % TFA in CH3CN) were
performed on a Shimadzu UFLC HPLC system
equipped with a DGU-20A degasser, a SPD-M20A UV
detector, a LC-20AB pump system, a CBM-20A com-
munication BUS module, a FRC-10A fraction col-
lector, and a Scan-RAM radio-TLC/HPLC-detector
from LabLogic using a reversed phase Atlantis® T3
column (C18, 5 μm, 4.6 mm × 250 mm). Quality con-
trols of radio-labeled compounds were analyzed using
a Shimadzu HPLC system with a Posi-Ram detector.
Electrospray ionization mass spectrometry (ESI-MS)
spectra were recorded with a Waters Acquity UPLC
(Milford, CA) with electrospray ionization SQ de-
tector. High-resolution mass spectrometry (HRMS)
spectra were recorded with a Waters LCT Premier
system (ESI). The radioactivity of the binding assaywas counted with a WIZARD2 automatic γ-counter
from Perkin Elmer (Boston, MA). Nunc™ Lab-Tek™ II
Chamber Slide™ Systems were analyzed by an inverted
confocal microscope (Leica TCS SP5 II) using an ob-
jective with ×20 magnification. MicroSuite FIVE soft-
ware was used to register images, and Fiji software
was used to manually adjust and analyze images. Small
animal PET imaging data were recorded on an Inveon®
PET/CT from Siemens (Knoxville, TN) and epifluores-
cence imaging was conducted with an IVIS spectrum
fluorescence imaging system (PerkinElmer).
Preparation of BODIPY-Fl-PEG4-Azide 1
A solution of 11-Azido-3,6,9-trioxaundecan-1-amine
(2.2 mg, 10 μmol, 1.1 eq.) in anhydrous dimethylforma-
mide (20 μL) was added slowly to a stirred solution of
BODIPY-Fl NHS ester (2.0 mg, 5.1 μmol, 1.0 eq.) and
N,N-Diisopropylethylamine (2.6 mg, 20 μmol, 0.8 eq.) in
anhydrous dimethylformamide (800 μL) at room
temperature and the resulting mixture was stirred in the
dark at room temperature for 2 h. Addition of water
(800 μL) and purification by HPLC (1 mL/min, 5 to
95 % B in 20 min) afforded 1 (2.5 mg, 99 %) as a red
solid; tR = 14.3 min. ESI-MS(+): m/z (%) = 515.3 (100)
[M +Na]+.
Preparation of 18F-BODIPY-azide 2
The radiolabeling of the BODIPY dye was performed ac-
cording to the isotope exchange method reported previ-
ously [6]. Briefly, the activated aqueous 18F solution is
transferred into a drying vessel containing tetra-n-buty-
lammonium hydrogen carbonate (80 μL) as a phase
transfer agent. Acetonitrile (3 × 3.0 mL) was added and
the solution of 18F was dried by heating to 100 °C with a
continuous flow of argon. After reconstitution of 18F
(44 ± 5 mCi) in anhydrous acetonitrile (100 μL), a solu-
tion of BODIPY-azide 1 (50 μg, 0.1 μmol) and SnCl4
(0.1 M in acetonitrile, 100 μL) was added to the solution
with the activity and the reaction solution was stirred at
37 °C for 30 min. After addition of water (400 μL), puri-
fication by HPLC (0.8 mL/min, 30 to 95 % B in 30 min)
afforded 2 (RCY: 3.8 ± 1.4 %) with a specific activity of
(5 ± 0.5 mCi/μmol).
Preparation of 18 F-BODIPY-BBN 3
To a solution of 18 F-BODIPY-azide 2 (700 ± 300 μCi),
BODIPY-azide 1 (50 μg, 0.10 μmol) and alkyne-
modified BBN 4 (0.16 mg, 0.10 μmol) in PBS (250 μL)
was added a premixed solution of CuSO4 (100 μg,
0.63 μmol) and ascorbic acid (550 μg, 3.1 μmol) in PBS
(63 μL). The reaction solution was stirred in the dark at
room temperature for 1 h. Addition of acetonitrile
(150 μL) and purification by HPLC (0.8 mL/min, 5 to
95 % B in 15.9 min) afforded 3 (decay-corrected RCY:
Paulus et al. EJNMMI Research  (2015) 5:43 Page 3 of 945 ± 4 %) with an estimated specific activity of (625 ±
100 μCi/μmol) and a radiochemical purity of >95 %.
Preparation of BODIPY-BBN 5
To a solution of BODIPY-azide 1 (0.4 mg, 0.8 μmol,
1.0 eq.) and alkyne-modified bombesin 4 (1.1 mg,
0.8 μmol, 1 eq.) in PBS (0.5 mL) was added a solution of
CuSO4 (0.8 mg, 5.0 μmol, 6.0 eq.) and ascorbic acid
(4.4 mg, 25 μmol, 31 eq.) in PBS (0.5 mL) and the result-
ing mixture was stirred in the dark at room temperature
for 1 h. Addition of acetonitrile (200 μL) and purification
by HPLC (1 mL/min, 5 % to 95 % B in 20 min) afforded
5 (0.4 mg, 27 %) as a red solid: tR = 11.1 min. ESI-MS(+):
m/z (%) = 914.0 (100) [M + 2H]2+. HRMS (ESI): m/z
calcd for C89H128BF2N22O17: 1826.9889; found: 1826.9968
[M+H]+.
Preparation of 18F-BODIPY-labeled peptides
Using the previous described click chemistry approach, we
attached successfully 18F-BODIPY-azide 2 to various pep-
tides, such as exendin-4, pHLIP, and CCK2 and obtained
three different peptidic dual-modality imaging agents:
Analytical data for 18F-BODIPY-CCK2: tr = 14.7 min; ESI-
MS(+): m/z (%) = 1134.2 (100) [M +Na +H]2+. Analytical
data for 18F-BODIPY-pHLIP: tr = 12.8 min; ESI-MS(+):
m/z (%) = 1168.7 (100) [M+Na + 3H]4+, 1557.8 (40) [M +
2H+Na]3. Analytical data for 18F-BODIPY-exendin-4:
tr = 13.2 min; ESI-MS(+): m/z (%) = 930.9 (35) [M + 5H]
+,
1157.8 (100) [M + 4H]4+, 1550.1 (30) [M + 3H]3+.
Cell culture
The human prostate cancer cell line PC-3, a G-protein
coupled receptor-positive cell line was used for in vitro
receptor-binding studies at passages 3–8. Cell culture
was performed as previously described [11]. The cells
were grown in F-12 K medium containing 2 mM L-glu-
tamine and 1500 mg/L sodium bicarbonate and passaged
regularly at 70–80 % confluence every 3–4 days. PC-3
cells were cultured according to the recommendations
of American Type Culture Collection and Caliper Life
Sciences under 37 °C with 5 % CO2.
Animals
All mouse model experiments and procedures were
performed in accordance with the guidelines set by
the Institutional Animal Care and Use Committee at
Memorial Sloan Kettering Cancer Center. Male athy-
mic nude mice (Charles River Lab; Cr1:Nu-Foxn1nu,
6–8 weeks, 20–25 g) were used for subcutaneous
mouse model. PC-3 cells (5.0 × 106) were suspended in
media (150 μL), mice were anesthetized with 2 % iso-
flurane gas in 2 L/min medical air, and PC-3 cells were
injected subcutaneously in the right shoulder to estab-
lish tumor-bearing mice (4–8 mm tumor diameter)after 2 weeks. For intravenous injections, mice were
gently heated with a heating lamp, placed on an injec-
tion restrainer, tail cleaned with sterilized alcohol
pads, and the imaging agent was injected to the lateral
tail vain.
In vitro cell imaging
To determine BODIPY-BBN uptake in vitro, PC-3
cells (1.0 × 104 per well) were seeded in a two-well
chamber slide (Nunc™ Lab-Tek™ II Chamber Slide™
System) containing growth media (1 mL) and incu-
bated at 37 °C for 24 h. To study the uptake of
BODIPY-BBN, PC-3 cells were incubated with 5 (10
nM in PBS, 37 °C for 30 min). At the same time block-
ing studies were performed. PC-3 cells were pre-
incubated with RM2 (1000 nM in PBS, 37 °C for
5 min) before incubation with BODIPY-BBN (10 nM
in PBS, 37 °C for 30 min). After washing with media
(1.0 mL), blue whole cell stain was added and incu-
bated at room temperature for 5 min. The cells were
washed with PBS (3 × 1.0 mL), living cells were imaged
using an inverted confocal microscope (Leica TCS SP5
II), and data were analyzed with Fiji.
In vitro receptor-binding assay
A competitive receptor-binding assay with [125I-Tyr4]-
bombesin was performed to determine the receptor-
binding affinity of BODIPY-BBN 5. PC-3 cells (5.0 × 105
cells per vial) were added to vials containing medium
(900 μL). For the assay, equal volumes (50 μL) of [125I-
Tyr4]-bombesin and BODIPY-BBN 5 were added. The
concentration of [125I-Tyr4]-bombesin was 10−12 M. In-
creasing concentrations (10−6 to 10-14) of BODIPY-BBN
5 were added. After agitation at room temperature for
2 h, the cells were harvested by a filter system. The filter
for each vial was collected and counted in a γ-counter.
Experiments as well as each data point were conducted
in triplicate. Data were analyzed with GraphPad Prism 6
Software to determine the IC50 value of BODIPY-BBN 5.
Surface fluorescence imaging
With the identified in vitro binding affinity of BODIPY-
BBN 5 to GRP receptor-positive PC-3 cells, surface
fluorescence imaging experiments with an IVIS
spectrum fluorescence imaging system (PerkinElmer)
were conducted with subcutaneous tumor-bearing
mice. Mice were injected intravenously with the im-
aging agent BODIPY-BBN 5 (33 μg, 18 nmol) in PBS
(5 % DMSO, 200 μL), sacrificed after 1 h post injec-
tion, and then ex vivo tumor as well as muscle epi-
fluorescence were quantified using Living Image® 4.3
software (Caliper Life Sciences). For a control experi-
ment, mice were injected with PBS (200 μL) and
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PET/CT imaging
Small animal PET/CT imaging was performed on an
Inveon® multi-modality PET/CT imaging scanner (Sie-
mens). 18F-BODIPY-BBN 3 (55 ± 10 μCi) in PBS (4 %
DMSO, 200 μL) was injected into tumor-bearing nude
mice (n = 3) via tail vain. At 30 min after injection, the
mice were anesthetized with 1.5-2.0 % isoflurane (Baxter
Healthcare) at 2 mL/min in oxygen and dynamic PET/
CT imaging was accomplished over 90 min. Images were
analyzed using AsiPro VM™ software (Concorde Micro-
systems) and Inveon research workplace 4.1 software
(Siemens Healthcare). After PET imaging, mice were
sacrificed by asphyxiation with CO2 and tumor as well
as muscle were harvested, weighed, and counted using a
WIZARD2 automatic γ-counter from Perkin Elmer. The
percentage of tracer uptake stated as percentage injected
dose per gram of tissue (%ID/g) was calculated as the ac-
tivity bound to tissue per organ weight per actual injected
dose, decay-corrected to the start time of counting.
Results
Our concept for the synthesis of bimodal imaging agents is
shown in Fig. 1. First, the azeotropic distillation of an aque-
ous fluorine-18 solution allows us to radiolabel an azide-
modified BODIPY-FL to yield a dual-modality (radioactive/
fluorescent) imaging agent. The clickable bimodal imaging
tracer is then conjugated in a bioorthogonal cycloaddition
reaction to various peptides, yielding dual-modality imaging
agents quickly via a modular synthetic protocol.
Synthesis of our 19F-labeled fluorescent analog BODIPY-
azide 1 started from commercial available BODIPY-Fl NHS
ester (Additional file 1: Figure S1A). The commercially
available amine reactive ester was reacted with 11-Azido-
3,6,9-trioxaundecan-1-amine and BODIPY-azide 1 was iso-
lated in 99 % yield after HPLC purification. The bombesin
analog RM2 (BBN) [12] was synthesized manually accord-
ing to standard Fmoc chemistry [13] and modified on theFig. 1 Conceptual design of the synthesis and application of a bimodal cli
radionuclide was reacted with the BF2 group of an azide-modified BODIPY
Cu-click protocol allowed the rapid conjugation of the azide dye to targete
synthetic effortN-terminus with the unnatural amino acid (S)-2-Amino-4-
pentynoic acid with a yield of 71 % (see Additional file 1:
Supporting information). Finally, bioorthogonal 1,3-di-
polar cycloaddition of BODIPY-azide 1 to alkyne-
modified BBN 4 afforded the BODIPY-BBN 5 in 34 %
yield (Additional file 1: Figure S2).
The radio-labeled dual-modality imaging agent 18F-
BODIPY-BBN 3 was synthesized by a two-step proced-
ure, similar to previous reports (Fig. 2a) [6, 8, 10]. First,
BODIPY-azide 1 was radio-labeled with 18F using the
strong Lewis acid SnCl4 in dry acetonitrile. After 30 min
of incubation, 18F-BODIPY-azide 2 was isolated by
HPLC purification in 3.8 ± 1.4 % radiochemical yield
(Fig. 2b). The resulting dual-modality imaging tool was
subjected to standard azide-alkyne cycloaddition (CuAAC)
reaction conditions (alkyne-modified BBN 4, ascorbic acid,
copper sulfate, and room temperature), yielding the
peptide-based dual-modality imaging agent. After HPLC
purification, the decay-corrected radiochemical yield for the
second synthetic step was determined to be 45 ± 4 %, with
a radiochemical purity of >95 %, and a specific activity of
625 μCi/μmol (Fig. 2b). BODIPY-azide 1 (50 μg) was added
to the reaction mixture to accelerate the 1,3-dipolar azide-
alkyne cycloaddition. The synthetic preparation of the dual-
modality peptide-based imaging agent was achieved in
2.5 h (including radiolabeling, HPLC purification of 2,
evaporation of solvents, copper-catalyzed [3 + 2] Huisgen
cycloaddition, HPLC purification of 3 and formulation of
an injectable solution).
To show the general applicability of this new ap-
proach, 18F-BODIPY-azide 2 was coupled to three other
peptides, which were previously described for imaging
of tumors by using either PET imaging or optical im-
aging (Fig. 3a) [5, 14–16]. Using standard click reaction
conditions, we successfully synthesized three different
dual-modality imaging agents with the same precursor
(Fig. 3b). For hydrophobic peptides (exendin-4 and
pHLIP), dimethylsulfoxide can be added to the reaction
solution to increase peptide solubility. HPLC ESI-MS
confirmed that the identity of the products where theck chemistry tool. After azeotropic distillation of [18 F]-F− n.c.a., the
-FL dye, yielding a 18 F-labeled, bimodal imaging agent. A modular
d peptides, quickly yielding a variety of compounds with only little
Fig. 2 Synthesis and analytical data of 18F-BODIPY-BBN 3. a Tin tetrachloride-catalyzed 18F-radiolabeling of BODIPY-Fl azide 1 followed by CuAAC
click chemistry with alkyne-modified bombesin analog (RM2-alkyne) to yield 18F-BODIPY-BBN 3. b HPLC chromatograms (radio trace and
absorbance at 500 nm) of 18F-BODIPY-N3 2 (left) and
18F-BODIPY-BBN 3 (right). c Electrospray ionization mass spectrometry of cold BODIPY-BBN
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sponded with the calculated molecular weight of the
click product.
The binding of BODIPY-BBN 5 toward GRP receptor
overexpressing PC-3 cells was evaluated in confocal live-
cell imaging (Fig. 4a). After incubation of BODIPY-BBN
5 (10 nM, 30 min), cells were treated with blue whole
cell stain (5 min) and washed with PBS. Confocal mi-
croscopy demonstrated antagonist-specific binding of
BODIPY-BBN 5 (green, top row) to the membrane sur-
face [12]. To show GRP receptor specificity of BODIPY-
BBN, PC-3 cells were pre-incubated with an excess of
unmodified GRP receptor antagonist [D-Phe6]-BN(6–
13)-ethylester which showed complete suppression of
green fluorescent signal (bottom row). We also confirmed
the binding affinity of BODIPY-BBN 5 using [125I-Tyr4]-
bombesin in a competitive binding assay (Fig. 4b). Com-
pared to an earlier reported IC50 of RM2 (7.7 ± 3.3 nM)
[12] we observed a slightly higher IC50 of 15 ± 3.5 nM
for our bimodal imaging agent BODIPY-BBN 5. We
then determined the stability of our imaging tracer in
human serum (37 °C) at pre-determined time points
showing >90 % intact fluorescent imaging agent after
60 min of incubation (Additional file 1: Figure S6).
After evaluating BODIPY-BBN 5 as a successful imaging
agent in vitro, we explored the dual-modality imaging prop-
erties (optical imaging as well as PET imaging) for GRP re-
ceptor overexpressed tumors using a PC-3 subcutaneoustumor mouse model (Fig. 5). After 1 h post intravenous in-
jection of BODIPY-BBN 5, ex vivo fluorescent imaging of
tumor and muscle revealed uptake of the imaging agent in
the tumor with GRP receptor overexpression (Fig. 5a). Ana-
log to this finding, the intensity of specific fluorescent signal
of the imaging agent yielded a tumor to muscle ratio of 5.7
(Additional file 1: Figure S4). Control mice, injected with
PBS (n = 3), did not show fluorescence in their tumor tis-
sue, yielding a tumor to muscle ratio of 0.21.
We injected tumor-bearing mice (PC-3, n = 3) with
18F-BODIPY-BBN 3 to determine the potential of the
probe as a whole-body imaging agent (Fig. 5b). Although
unexpected high liver and bone uptake were observed,
we could clearly visualize the tumor with 1.2 ± 0.2 per-
cent injected dose per gram (%ID/g) in PET/CT images
30 min post intravenous injection of 18F-BODIPY-BBN
3 (55 ± 10 μCi). After PET/CT imaging, mice were sacri-
ficed, organs of interest (tumor as well as muscle) were
harvested, and the specific uptake of tracer was deter-
mined by gamma-counting. Mirroring the optical im-
aging, we observed a tumor to background ratio of 5.2
(Additional file 1: Figure S4).
Discussion
Positron emission tomography is a well-established diag-
nostic tool in modern medicine, particularly in oncology.
During the last decade, tremendous success has been
achieved in the development of novel peptide-based
Fig. 3 Application of the bimodal click chemistry tool for the synthesis of dual-modality peptidic imaging agents. a Overview of three
alkyne-modified peptides and the click products with their molecular weights. b HPLC chromatograms and ESI-MS data of the synthesized
dual-modality peptide-based imaging agents
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peptide-based imaging probe, PET can be used for the
visualization as well as the quantification of cancer cell-
specific protein overexpression in tumor tissue [19].
However, PET imaging has its limitation in spatial reso-
lution [1]. A dual-modality imaging probe that is both
radioactive as well as fluorescent can overcome this limi-
tation and allows imaging from the whole-body to the
cellular level.
Over the last years, the development of dual-modality
imaging platforms—combining PET imaging and optical
imaging—has evolved into a fast growing research field
[20, 21]. Several reports also describe the synthesis of
dual-modality peptide-based imaging agents [4, 22, 23].
In 2009, Kimura et al. developed a cross-linking strategy
for stoichiometric coupling of DOTA for radiolabeling
with 64Cu as well as near-infrared dye Cy5.5 for optical
imaging to a disulfide knottin peptide [23]. They,however, observed higher kidney and less tumor uptake
of the dual-modality integrin receptor imaging agent,
presumably due to the bulkiness of the conjugated im-
aging tag. In 2014, our group presented a linear ap-
proach for the synthesis of a dual-modality imaging
agent to reduce the impact of the bimodal imaging tag
[5]. Here, the conjugation of the bimodal tag containing
the fluorescent dye, together with the hexaamine copper
chelator DiAmSar, resulted in a decreased binding affinity
of the dual-modality imaging tracer compared to just a
PET [24] or a fluorescent [25–27] exendin-4-based imaging
agent.
In order to avoid an impact on target binding and bio-
distribution, the design of a dual-modality imaging agent
should ideally aim for the incorporation of a fluoro-
chrome as well as radionuclide with a small “footprint”.
We therefore developed a clickable 18F-BODIPY-azide
bimodal imaging tool for site-specific conjugation to
Fig. 4 In vitro uptake and inhibition studies of BODIPY-BBN 5 using GRP receptor overexpressing PC-3 cells. a Confocal microscopy imaging
experiment demonstrated cell surface binding of the green fluorescent imaging agent in the green channel (BODIPY, top row); Nuclei were
counterstained with Hoechst dye (blue, top row); Blocking studies of BODIPY-BBN 5 were performed with a 100-fold excess of unlabeled GRP
receptor antagonist [D-Phe6]-BN(6–13)-ethylester (bottom row). b IC50 values of 5 were evaluated by a competitive binding assay
using [125I-Tyr4]-bombesin
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on several previous studies which have indicated the
feasibility of using BODIPY dyes as bimodal imaging
agents bimodal [6–8]. The principal advantage of this
approach is that the chemical properties of the optical
and bimodal optical/nuclear imaging agent are the same
(Fig. 1). However, it is to mention that labeling first and
then clicking the dual-modality imaging tracer to a pep-
tide in general leads to lower specific activities than
some other labeling approaches.
Keliher et al. recently showed that the labeling effi-
ciency is strongly dependent on the type of BODIPY dye
[8]. Their conversion after 30 min incubation reachesfrom 16 to 90 % with the same labeling procedure for
different dyes. Similar results were obtained by Liu et al.
[6] and Hendricks et al. [7]. Hendricks also observed
high in vivo stability, which was shown by injecting a
non-targeted 18F-BODIPY small molecule, demonstrat-
ing no release of radioactive fluorine. In comparison to
these previously reported studies, our in vivo experi-
ments resulted in a much higher uptake of radioactivity
in bone, which likely originates from free 18F. We as-
sume that the accumulation of activity in the bones is
based on insufficient metabolic stability of the borane-
fluorine bond of 18F-BODIPY-BBN 3. One reason for
the decreased in vivo stability of our probe, compared to
Fig. 5 Visualization of PC-3 tumors by optical imaging as well as PET imaging using the dual-modality imaging agent 18F-BODIPY-BBN. a Ex vivo
fluorescent imaging of tumor and muscle after intravenous injection of BODIPY-BBN 5 (18 nmol) in PBS (4 % DMSO, 200 μL); For a control experiment
PC-3 tumor-bearing mice were injected with PBS (4 % DMSO, 200 μL); scale bar: 5 mm. b In vivo small animal PET/CT images (30 min) after intravenous
injection of 18F-BODIPY-BBN 3 (55 ± 10 μCi) in PBS (4 % DMSO, 200 μL)
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core structures have different metabolic half lifes.
Conclusions
In summary, we investigated the synthesis and applica-
tion of a clickable bimodal fluorescent/PET imaging tool.
With the successful incorporation of 18F into a clickable
BODIPY-Fl linker, we were able to site-specifically con-
jugate the dual-modality imaging tracer to four different
peptides. We then investigated the properties of 18F-
BODIPY-BBN as a GRP receptor targeting imaging
agent in vitro as well as in vivo. Even though we could
visualize a tumor in PC-3 xenograft mouse model by
ex vivo surface fluorescent imaging as well as whole-
body PET imaging, further studies with different—and
potentially more stable—BODIPY dyes will be con-
ducted to reduce the off target bone uptake.
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